Invasive Pneumococcal Disease in the Immunocompromised

Pneumococcal vaccines are reducing IPD incidence in immunocompromised patients, but they still get IPD much more often than immunocompetent people.

Given the high morbidity and mortality from invasive pneumococcal disease (IPD), pneumococcal vaccines are especially important for immunocompromised patients. To better characterize this population, researchers analyzed 7604 episodes of IPD that occurred in metropolitan Toronto and the Peel region of Canada from 1995 to 2012.

IPD incidence was 28% among immunocompromised patients, a statistically significant 12-fold higher than among immunocompetent people. Immunocompromised patients represented 9.3% of the IPD cases among children, 34.5% among young adults, and 29.9% among patients age 65 or older. The most common underlying conditions in immunocompromised patients were acute leukemia in children, HIV infection in young adults, and chronic…

Reviewing Author

Stephen G. Baum, MD

Disclosures

Consultant/Advisory BoardClinical Infectious Diseases

RoyaltiesUpToDate

Editorial BoardsMedical Letter

Stephen G. Baum, MD

Disclosures

Consultant/Advisory BoardClinical Infectious Diseases

RoyaltiesUpToDate

Editorial BoardsMedical Letter

Invasive Pneumococcal Disease in the Immunocompromised

Topics

Reviewing Author